CA2817709C - Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same - Google Patents

Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same Download PDF

Info

Publication number
CA2817709C
CA2817709C CA2817709A CA2817709A CA2817709C CA 2817709 C CA2817709 C CA 2817709C CA 2817709 A CA2817709 A CA 2817709A CA 2817709 A CA2817709 A CA 2817709A CA 2817709 C CA2817709 C CA 2817709C
Authority
CA
Canada
Prior art keywords
same
nucleic acid
acid sequences
vaccine
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2817709A
Other languages
English (en)
French (fr)
Other versions
CA2817709A1 (en
Inventor
David B. Weiner
Jian Yan
Bernadette Ferraro
Niranjan Y. Sardesai
Mathura P. Ramanathan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Inovio Pharmaceuticals Inc
Original Assignee
University of Pennsylvania Penn
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn, Inovio Pharmaceuticals Inc filed Critical University of Pennsylvania Penn
Publication of CA2817709A1 publication Critical patent/CA2817709A1/en
Application granted granted Critical
Publication of CA2817709C publication Critical patent/CA2817709C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y116/00—Oxidoreductases oxidizing metal ions (1.16)
    • C12Y116/01—Oxidoreductases oxidizing metal ions (1.16) with NAD+ or NADP+ as acceptor (1.16.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21077—Semenogelase (3.4.21.77), i.e. prostate specific antigen or PSA or kallikrein 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2817709A 2010-11-12 2011-11-14 Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same Active CA2817709C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41317610P 2010-11-12 2010-11-12
US61/413,176 2010-11-12
US41781710P 2010-11-29 2010-11-29
US61/417,817 2010-11-29
PCT/US2011/060592 WO2012065164A2 (en) 2010-11-12 2011-11-14 Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same

Publications (2)

Publication Number Publication Date
CA2817709A1 CA2817709A1 (en) 2012-05-18
CA2817709C true CA2817709C (en) 2021-06-01

Family

ID=46051609

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2817709A Active CA2817709C (en) 2010-11-12 2011-11-14 Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same

Country Status (16)

Country Link
US (6) US8927692B2 (enExample)
EP (3) EP3536703B1 (enExample)
JP (6) JP6077450B2 (enExample)
KR (5) KR102364214B1 (enExample)
CN (2) CN103314002B (enExample)
AU (1) AU2011325893B2 (enExample)
BR (1) BR112013011705B1 (enExample)
CA (1) CA2817709C (enExample)
DK (1) DK2638055T3 (enExample)
EA (1) EA027315B1 (enExample)
ES (1) ES2718846T3 (enExample)
MX (3) MX358725B (enExample)
PL (1) PL3536703T3 (enExample)
SI (1) SI3536703T1 (enExample)
WO (1) WO2012065164A2 (enExample)
ZA (1) ZA201303390B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HUE069586T2 (hu) 2010-10-01 2025-03-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása
EP3536703B1 (en) * 2010-11-12 2021-05-26 The Trustees of the University of Pennsylvania Consensus prostate antigens, nucleic acid molecules encoding the same and uses thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP6189415B2 (ja) 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
KR20200075023A (ko) * 2012-05-04 2020-06-25 화이자 인코포레이티드 전립선 관련된 항원 및 백신 기재 면역치료 요법
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
WO2014093886A1 (en) * 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Wt1 vaccine
EA201591131A1 (ru) 2012-12-13 2015-12-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Днк-конструкции антитела и способ их применения
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
MX369709B (es) * 2013-03-15 2019-11-19 Univ Pennsylvania Vacunación mejorada contra tirosinasa.
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
PE20171142A1 (es) 2013-11-01 2017-08-10 Pfizer Vectores para expresion de antigenos asociados a prostata
HUE069802T2 (hu) 2014-04-23 2025-04-28 Modernatx Inc Nukleinsav vakcinák
EP3226892A4 (en) 2014-12-01 2018-07-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
SG11201808152PA (en) * 2016-03-21 2018-10-30 David Weiner Dna antibody constructs and method of using same
JP6983819B2 (ja) * 2016-06-03 2021-12-17 エトゥビクス コーポレーション 前立腺がん関連抗原を使用する腫瘍ワクチン接種用の組成物及び方法
CN106119231A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种肿瘤抗原psa的ctl识别表位肽及其应用
CN106581668B (zh) * 2016-12-31 2020-03-24 广州姿生生物科技有限公司 一种抗原表位肽组合物及其应用
CA3083532C (en) * 2017-12-13 2023-09-05 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting prame and uses thereof
CN111308327B (zh) * 2019-12-02 2021-01-26 电子科技大学 模拟电路故障定位与故障元件参数辨识方法
US20250269010A1 (en) * 2021-02-05 2025-08-28 St Pharm Co., Ltd. Novel nucleic acid molecule

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
WO1990010693A1 (en) 1989-03-08 1990-09-20 Health Research, Inc. Recombinant poxvirus host selection system
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
DE69027313T2 (de) 1989-03-31 1997-01-23 Univ Washington Impfstoffe enthaltende avirulente phop-type mikroorganismen
EP0431668B1 (en) 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
WO1993025673A1 (en) 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
DE69334071T2 (de) * 1992-11-05 2007-10-25 Sloan-Kettering Institute For Cancer Research Prostata-spezifisches membranantigen
DK0681483T3 (da) 1993-01-26 2005-11-21 Univ Pennsylvania Præparater og fremgangsmåder til administration af genetisk materiale
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
CA2164505A1 (en) 1993-06-07 1994-12-22 Phillip W. Berman Hiv envelope polypeptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US6630305B1 (en) * 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CN1198665C (zh) 1997-04-03 2005-04-27 依莱克脱罗弗克脱联合股份有限公司 将药物和核酸导入骨骼肌的方法
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
BR9810369A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
IL139699A0 (en) * 1998-06-01 2002-02-10 Urogenesys Inc Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) * 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
EP1100579B1 (en) 1998-07-13 2015-09-02 Inovio Pharmaceuticals, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6136703A (en) 1998-09-03 2000-10-24 Micron Technology, Inc. Methods for forming phosphorus- and/or boron-containing silica layers on substrates
CN1325115C (zh) 1998-10-05 2007-07-11 法麦克萨有限公司 Ctl表位和t辅助淋巴细胞表位在免疫接种中的应用
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US20020081680A1 (en) 2000-04-17 2002-06-27 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
AU2002336446B2 (en) * 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
WO2004016225A2 (en) 2002-08-19 2004-02-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20040175727A1 (en) 2002-11-04 2004-09-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
NZ578591A (en) * 2003-05-30 2011-01-28 Agensys Inc Prostate stem cell antigen (PSCA) variants and subsequences thereof, namely SEQ ID NO: 6554
EP2364769B1 (en) 2003-05-30 2016-01-13 VGXI, Inc. Devices and methods for biomaterial production
WO2005071093A2 (en) 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Chimpanzee adenovirus vaccine carriers
JP2008518584A (ja) * 2004-05-27 2008-06-05 セントカー・インコーポレーテツド カニクイザルの前立腺特異的抗原
KR100647847B1 (ko) 2005-05-27 2006-11-23 크레아젠 주식회사 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 및 치료 효능을 분석하는 방법
US8293701B2 (en) * 2005-06-21 2012-10-23 Cellectis S.A. Methods and compositions relating to a vaccine against prostate cancer
WO2007056847A1 (en) * 2005-11-21 2007-05-24 Sanofi Pasteur Limited Stabilizing formulations for recombinant viruses
EP2061814B1 (en) 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US8852609B2 (en) * 2008-04-04 2014-10-07 The Trustees Of The University Of Pennsylvania Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
WO2010027513A2 (en) * 2008-09-08 2010-03-11 Psma Development Company, Llc Methods for killing psma-expressing, taxane-resistant cancer cells
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010050939A1 (en) * 2008-10-29 2010-05-06 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
WO2010057159A2 (en) * 2008-11-17 2010-05-20 Vgx Pharmaceuticals, Llc Antigens that elicit immune response against flavivirus and methods of using same
EP3536703B1 (en) * 2010-11-12 2021-05-26 The Trustees of the University of Pennsylvania Consensus prostate antigens, nucleic acid molecules encoding the same and uses thereof
CN104168912B (zh) * 2011-11-10 2016-08-24 北京艾棣维欣生物技术有限公司 促进剂-dna组合疫苗
CN110573173B (zh) * 2016-09-30 2024-11-08 宾夕法尼亚大学理事会 Tert免疫原性组合物及使用其的治疗方法

Also Published As

Publication number Publication date
KR20200084067A (ko) 2020-07-09
US20250101399A1 (en) 2025-03-27
US20150150957A1 (en) 2015-06-04
JP2014500724A (ja) 2014-01-16
EP3536703A1 (en) 2019-09-11
JP2021045171A (ja) 2021-03-25
EP2638055B1 (en) 2019-01-09
EP3909973A2 (en) 2021-11-17
JP6310952B2 (ja) 2018-04-11
JP2018030881A (ja) 2018-03-01
EA201390689A1 (ru) 2013-11-29
EP2638055A4 (en) 2015-12-30
CN103314002B (zh) 2016-09-07
CN103314002A (zh) 2013-09-18
KR101939150B1 (ko) 2019-01-17
MX421208B (es) 2025-02-10
CN106434676A (zh) 2017-02-22
AU2011325893B2 (en) 2016-01-14
JP6077450B2 (ja) 2017-02-08
US11045535B2 (en) 2021-06-29
KR102131276B1 (ko) 2020-07-08
WO2012065164A3 (en) 2012-07-26
CN106434676B (zh) 2020-10-23
US9913885B2 (en) 2018-03-13
JP2016093199A (ja) 2016-05-26
JP2023171837A (ja) 2023-12-05
MX2013005195A (es) 2013-08-27
WO2012065164A2 (en) 2012-05-18
BR112013011705B1 (pt) 2022-04-05
CA2817709A1 (en) 2012-05-18
ZA201303390B (en) 2016-02-24
JP7142427B2 (ja) 2022-09-27
EP2638055A2 (en) 2013-09-18
KR20140004098A (ko) 2014-01-10
PL3536703T3 (pl) 2021-10-25
KR102557275B1 (ko) 2023-07-19
MX2018010616A (es) 2022-08-24
KR20170141811A (ko) 2017-12-26
KR20220025242A (ko) 2022-03-03
AU2011325893A1 (en) 2013-05-30
JP7572152B2 (ja) 2024-10-23
MX346784B (es) 2017-03-31
US8927692B2 (en) 2015-01-06
ES2718846T3 (es) 2019-07-04
EP3909973A3 (en) 2022-01-26
JP2020108396A (ja) 2020-07-16
US20190046621A1 (en) 2019-02-14
US11980659B2 (en) 2024-05-14
US20220016228A1 (en) 2022-01-20
US9399056B2 (en) 2016-07-26
BR112013011705A2 (pt) 2018-03-13
KR102011026B1 (ko) 2019-08-14
DK2638055T3 (en) 2019-04-23
EA027315B1 (ru) 2017-07-31
US20160361403A1 (en) 2016-12-15
EP3536703B1 (en) 2021-05-26
SI3536703T1 (sl) 2022-04-29
KR102364214B1 (ko) 2022-02-17
MX358725B (es) 2018-09-03
KR20190096447A (ko) 2019-08-19
US20130302361A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
CA2817709C (en) Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
MX2013008836A (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
MX2018008135A (es) Moleculas de acido nucleico de influenza y vacunas elaboradas a partir de las mismas.
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
MY162737A (en) 4-1bb binding molecules
EP3950941A3 (en) Dnase polypeptide variants
MX2013007997A (es) Polipeptidos que tienen actividad de incremento celulolitico y polinucleotidos que codifican para los mismos.
EP3563865A3 (en) Prostate-associated antigens and vaccine-based immunotherapy regimens
IN2014CN04586A (enExample)
MY156286A (en) Human il-23 antigen binding proteins
MX356647B (es) Polipeptidos que tienen actividad de fosfolipasa c y polinucleotidos que codifican los mismos.
MX2020001385A (es) Composiciones que comprenden construcciones geneticas y vacunas de il-12 mejoradas, agentes inmunoterapeuticos y metodos para su uso.
MX2014004598A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX354704B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
MX349517B (es) Polipeptidos que tienen actividad de proteasa y polinucleotidos que codifican los mismos.
MX2014003403A (es) Polipeptidos que poseen actividad proteasa y polinucleotidos que los codifican.
MX2014007446A (es) Variantes de subtilasa y polinucleotidos que las codifican.
MX350713B (es) Variantes de subtilisina y polinucleotidos que las codifican.
WO2012026820A3 (en) Immunotherapeutic method for treating prostate cancer
NZ741667A (en) Prostate-associated antigens and vaccine-based immunotherapy regimens
CL2010000466A1 (es) Genes de dc-sign, icam-3 y lsectin porcinas y usos delos mismos

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161103